SCHEMBL23102121

SCHEMBL23102121

COC1CCN(S(=O)(=O)N2CCCN(CC3CCCCC3)CCCN(S(=O)(=O)c3ccc(N(C)C)cc3)CC3(CC3)C2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.41
NR3C1 P04150 2/20 0.38
TSHR P16473 3/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
XBP1 P17861 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
KCNH2 Q12809 2/20 0.36
HRH3 Q9Y5N1 2/20 0.36
CYP1A2 P05177 4/20 0.35
CYP3A4 P08684 4/20 0.35
CYP2D6 P10635 4/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 1/20 0.35
USP2 O75604 2/20 0.35
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23102163 0.92 TSHR (0.44) NR3C1TSHRMEN1KMT2AXBP1
SCHEMBL23102233 0.92 TSHR (0.44) NR3C1TSHRMEN1KMT2AXBP1
SCHEMBL21361559 0.92 TSHR (0.44) NR3C1TSHRMEN1KMT2AXBP1
Hydrochloric Acid SCHEMBL21359222 0.91 TSHR (0.43) NR3C1TSHRMEN1KMT2AXBP1
SCHEMBL23102243 0.91 KMT2A (0.43) NR3C1TSHRMEN1KMT2AXBP1
SCHEMBL23102111 0.90 HSD11B1 (0.39) HSD11B1NR3C1TSHRMEN1KMT2A
SCHEMBL23102166 0.89 TSHR (0.39) HSD11B1NR3C1TSHRMEN1KMT2A
SCHEMBL25388946 0.87 CYP3A4 (0.41) NR3C1TSHRMEN1KMT2AXBP1
SCHEMBL23102161 0.86 ALDH1A1 (0.43) TSHRMEN1KMT2AXBP1OPRM1
SCHEMBL23102239 0.85 NPSR1 (0.44) NR3C1TSHRMEN1KMT2AXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G HSD11B1 258/4885NR3C1 2439/4885TSHR 727/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G HSD11B1 290/4885NR3C1 2660/4885TSHR 976/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G HSD11B1 274/4885NR3C1 2192/4885TSHR 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.